AM J PATHOL 润色咨询

AMERICAN JOURNAL OF PATHOLOGY

出版年份:1925 年文章数:6304 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:1.8% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:终于中了,大修修回二审11天,accept !数据量大,形式审查严格,非常正规的杂志,口碑巨佳,非常respective!除了因子不高,其他都是远超综合类五六分,以及个别领域虚高因子的期刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=730, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向:细胞机制研究;代谢性疾病;中性粒细胞<br>经验分享:想问问大家,这个杂志审稿速度快嘛,现在的状态是Submitted to Journal。要交50美金才审嘛?怎么在投稿要求中没看见啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀,是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0<br>经验分享:已经送审40天了,还没消息,还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向:肥胖<br>经验分享:请问这个杂志一般邀请几个审稿人啊?我under review 2个礼拜后,审稿日期刷新了2次,请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快,直接小修然后接受。老牌病理杂志,有较高的声誉。我做的并不是纯病理,是与疾病相关的研究,药物治疗,有IHC等病理检测,感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:难度挺大的期刊,实验室之前投了几篇都悲剧了,后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了,很开心,就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2020-08-16 ms4000001908142028

    审稿速度:6.0 | 投稿命中率:25.0
    经验分享:终于中了,大修修回二审11天,accept !数据量大,形式审查严格,非常正规的杂志,口碑巨佳,非常respective!除了因子不高,其他都是远超综合类五六分,以及个别领域虚高因子的期刊!

    9

    展开9条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:终于中了,大修修回二审11天,accept !数据量大,形式审查严格,非常正规的杂志,口碑巨佳,非常respective!除了因子不高,其他都是远超综合类五六分,以及个别领域虚高因子的期刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=730, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向:细胞机制研究;代谢性疾病;中性粒细胞<br>经验分享:想问问大家,这个杂志审稿速度快嘛,现在的状态是Submitted to Journal。要交50美金才审嘛?怎么在投稿要求中没看见啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀,是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0<br>经验分享:已经送审40天了,还没消息,还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向:肥胖<br>经验分享:请问这个杂志一般邀请几个审稿人啊?我under review 2个礼拜后,审稿日期刷新了2次,请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快,直接小修然后接受。老牌病理杂志,有较高的声誉。我做的并不是纯病理,是与疾病相关的研究,药物治疗,有IHC等病理检测,感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:难度挺大的期刊,实验室之前投了几篇都悲剧了,后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了,很开心,就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2023-04-22 晨曦呀 来自浙江省

    偏重的研究方向:细胞机制研究;代谢性疾病;中性粒细胞
    经验分享:想问问大家,这个杂志审稿速度快嘛,现在的状态是Submitted to Journal。要交50美金才审嘛?怎么在投稿要求中没看见啊?

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:终于中了,大修修回二审11天,accept !数据量大,形式审查严格,非常正规的杂志,口碑巨佳,非常respective!除了因子不高,其他都是远超综合类五六分,以及个别领域虚高因子的期刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=730, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向:细胞机制研究;代谢性疾病;中性粒细胞<br>经验分享:想问问大家,这个杂志审稿速度快嘛,现在的状态是Submitted to Journal。要交50美金才审嘛?怎么在投稿要求中没看见啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀,是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0<br>经验分享:已经送审40天了,还没消息,还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向:肥胖<br>经验分享:请问这个杂志一般邀请几个审稿人啊?我under review 2个礼拜后,审稿日期刷新了2次,请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快,直接小修然后接受。老牌病理杂志,有较高的声誉。我做的并不是纯病理,是与疾病相关的研究,药物治疗,有IHC等病理检测,感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:难度挺大的期刊,实验室之前投了几篇都悲剧了,后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了,很开心,就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2023-05-26 庸医小王 来自湖北省

    审稿速度:1.0 | 投稿命中率:95.0
    经验分享:May 25, 2023 Submitted to Journal

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:终于中了,大修修回二审11天,accept !数据量大,形式审查严格,非常正规的杂志,口碑巨佳,非常respective!除了因子不高,其他都是远超综合类五六分,以及个别领域虚高因子的期刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=730, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向:细胞机制研究;代谢性疾病;中性粒细胞<br>经验分享:想问问大家,这个杂志审稿速度快嘛,现在的状态是Submitted to Journal。要交50美金才审嘛?怎么在投稿要求中没看见啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀,是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0<br>经验分享:已经送审40天了,还没消息,还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向:肥胖<br>经验分享:请问这个杂志一般邀请几个审稿人啊?我under review 2个礼拜后,审稿日期刷新了2次,请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快,直接小修然后接受。老牌病理杂志,有较高的声誉。我做的并不是纯病理,是与疾病相关的研究,药物治疗,有IHC等病理检测,感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:难度挺大的期刊,实验室之前投了几篇都悲剧了,后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了,很开心,就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2021-11-23 ms4000000531440481

    请问我的文章一直是submitted to journal是啥情况呀,是不是这本刊物的这段过程都要经历这么久呢

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:终于中了,大修修回二审11天,accept !数据量大,形式审查严格,非常正规的杂志,口碑巨佳,非常respective!除了因子不高,其他都是远超综合类五六分,以及个别领域虚高因子的期刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=730, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向:细胞机制研究;代谢性疾病;中性粒细胞<br>经验分享:想问问大家,这个杂志审稿速度快嘛,现在的状态是Submitted to Journal。要交50美金才审嘛?怎么在投稿要求中没看见啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀,是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0<br>经验分享:已经送审40天了,还没消息,还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向:肥胖<br>经验分享:请问这个杂志一般邀请几个审稿人啊?我under review 2个礼拜后,审稿日期刷新了2次,请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快,直接小修然后接受。老牌病理杂志,有较高的声誉。我做的并不是纯病理,是与疾病相关的研究,药物治疗,有IHC等病理检测,感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:难度挺大的期刊,实验室之前投了几篇都悲剧了,后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了,很开心,就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2023-02-04 qyzhangsai 来自山东省

    投稿命中率:50.0
    经验分享:已经送审40天了,还没消息,还要等多久啊

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:终于中了,大修修回二审11天,accept !数据量大,形式审查严格,非常正规的杂志,口碑巨佳,非常respective!除了因子不高,其他都是远超综合类五六分,以及个别领域虚高因子的期刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=730, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向:细胞机制研究;代谢性疾病;中性粒细胞<br>经验分享:想问问大家,这个杂志审稿速度快嘛,现在的状态是Submitted to Journal。要交50美金才审嘛?怎么在投稿要求中没看见啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀,是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0<br>经验分享:已经送审40天了,还没消息,还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向:肥胖<br>经验分享:请问这个杂志一般邀请几个审稿人啊?我under review 2个礼拜后,审稿日期刷新了2次,请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快,直接小修然后接受。老牌病理杂志,有较高的声誉。我做的并不是纯病理,是与疾病相关的研究,药物治疗,有IHC等病理检测,感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:难度挺大的期刊,实验室之前投了几篇都悲剧了,后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了,很开心,就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2022-11-01 12201bb7m09(暂无昵称)

    偏重的研究方向:肥胖
    经验分享:请问这个杂志一般邀请几个审稿人啊?我under review 2个礼拜后,审稿日期刷新了2次,请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗?

    4

    展开4条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:终于中了,大修修回二审11天,accept !数据量大,形式审查严格,非常正规的杂志,口碑巨佳,非常respective!除了因子不高,其他都是远超综合类五六分,以及个别领域虚高因子的期刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=730, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向:细胞机制研究;代谢性疾病;中性粒细胞<br>经验分享:想问问大家,这个杂志审稿速度快嘛,现在的状态是Submitted to Journal。要交50美金才审嘛?怎么在投稿要求中没看见啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀,是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0<br>经验分享:已经送审40天了,还没消息,还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向:肥胖<br>经验分享:请问这个杂志一般邀请几个审稿人啊?我under review 2个礼拜后,审稿日期刷新了2次,请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快,直接小修然后接受。老牌病理杂志,有较高的声誉。我做的并不是纯病理,是与疾病相关的研究,药物治疗,有IHC等病理检测,感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:难度挺大的期刊,实验室之前投了几篇都悲剧了,后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了,很开心,就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2019-06-26 石榴

    审稿较快,直接小修然后接受。老牌病理杂志,有较高的声誉。我做的并不是纯病理,是与疾病相关的研究,药物治疗,有IHC等病理检测,感觉这个杂志并不局限于病理。

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:终于中了,大修修回二审11天,accept !数据量大,形式审查严格,非常正规的杂志,口碑巨佳,非常respective!除了因子不高,其他都是远超综合类五六分,以及个别领域虚高因子的期刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=730, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向:细胞机制研究;代谢性疾病;中性粒细胞<br>经验分享:想问问大家,这个杂志审稿速度快嘛,现在的状态是Submitted to Journal。要交50美金才审嘛?怎么在投稿要求中没看见啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀,是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0<br>经验分享:已经送审40天了,还没消息,还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向:肥胖<br>经验分享:请问这个杂志一般邀请几个审稿人啊?我under review 2个礼拜后,审稿日期刷新了2次,请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快,直接小修然后接受。老牌病理杂志,有较高的声誉。我做的并不是纯病理,是与疾病相关的研究,药物治疗,有IHC等病理检测,感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:难度挺大的期刊,实验室之前投了几篇都悲剧了,后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了,很开心,就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2021-12-29 衣谷

    选刊时有哪些需要避免的雷区?

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:终于中了,大修修回二审11天,accept !数据量大,形式审查严格,非常正规的杂志,口碑巨佳,非常respective!除了因子不高,其他都是远超综合类五六分,以及个别领域虚高因子的期刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=730, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向:细胞机制研究;代谢性疾病;中性粒细胞<br>经验分享:想问问大家,这个杂志审稿速度快嘛,现在的状态是Submitted to Journal。要交50美金才审嘛?怎么在投稿要求中没看见啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀,是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0<br>经验分享:已经送审40天了,还没消息,还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向:肥胖<br>经验分享:请问这个杂志一般邀请几个审稿人啊?我under review 2个礼拜后,审稿日期刷新了2次,请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快,直接小修然后接受。老牌病理杂志,有较高的声誉。我做的并不是纯病理,是与疾病相关的研究,药物治疗,有IHC等病理检测,感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:难度挺大的期刊,实验室之前投了几篇都悲剧了,后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了,很开心,就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2021-12-29 学医的彭于晏

    哪些期刊是公认的水刊?

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=809297, encodeId=fe3e80929ea9, content=审稿速度:6.0 | 投稿命中率:25.0<br>经验分享:终于中了,大修修回二审11天,accept !数据量大,形式审查严格,非常正规的杂志,口碑巨佳,非常respective!除了因子不高,其他都是远超综合类五六分,以及个别领域虚高因子的期刊!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=730, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ab4d5408378, createdName=ms4000001908142028, createdTime=Sun Aug 16 07:33:39 CST 2020, time=2020-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2127618, encodeId=9d45212e6188f, content=偏重的研究方向:细胞机制研究;代谢性疾病;中性粒细胞<br>经验分享:想问问大家,这个杂志审稿速度快嘛,现在的状态是Submitted to Journal。要交50美金才审嘛?怎么在投稿要求中没看见啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f6945549247, createdName=晨曦呀, createdTime=Sat Apr 22 09:45:26 CST 2023, time=2023-04-22, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2139144, encodeId=bfc52139144f8, content=审稿速度:1.0 | 投稿命中率:95.0<br>经验分享:May 25, 2023 Submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230516/a5876ef59b2b4825ad581eb6cfd86daf/6ba028f9262342b795ff62bc10dacb71.png, createdBy=22bd5254581, createdName=庸医小王, createdTime=Fri May 26 11:36:27 CST 2023, time=2023-05-26, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=1073347, encodeId=80cf10e334768, content=请问我的文章一直是submitted to journal是啥情况呀,是不是这本刊物的这段过程都要经历这么久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51aa5682119, createdName=ms4000000531440481, createdTime=Tue Nov 23 23:45:21 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2112987, encodeId=699f211298eb6, content=投稿命中率:50.0<br>经验分享:已经送审40天了,还没消息,还要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57703023475, createdName=qyzhangsai, createdTime=Sat Feb 04 12:06:02 CST 2023, time=2023-02-04, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2097908, encodeId=95cf209e90831, content=偏重的研究方向:肥胖<br>经验分享:请问这个杂志一般邀请几个审稿人啊?我under review 2个礼拜后,审稿日期刷新了2次,请问是2个审稿人意见不一致编辑又另外找第三个审稿人了吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e99d2299080, createdName=12201bb7m09(暂无昵称), createdTime=Tue Nov 01 19:32:40 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=572969, encodeId=17e15e296912, content=审稿较快,直接小修然后接受。老牌病理杂志,有较高的声誉。我做的并不是纯病理,是与疾病相关的研究,药物治疗,有IHC等病理检测,感觉这个杂志并不局限于病理。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=155, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fed1692442, createdName=石榴, createdTime=Wed Jun 26 13:59:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086485, encodeId=5c4c1086485f7, content=选刊时有哪些需要避免的雷区?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=72, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1086486, encodeId=6ea1108648654, content=哪些期刊是公认的水刊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Wed Dec 29 14:52:47 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578367, encodeId=07d95e8367e7, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:难度挺大的期刊,实验室之前投了几篇都悲剧了,后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了,很开心,就是分低了点。希望AJP能再现辉煌。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=216, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a9a2573861, createdName=1258c15em32暂无昵称, createdTime=Wed Oct 23 00:00:00 CST 2019, time=2019-10-23, status=1, ipAttribution=)]
    2019-10-23 1258c15em32暂无昵称

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享:难度挺大的期刊,实验室之前投了几篇都悲剧了,后面改投高两分的cell death & disease 反倒中了。我这篇文章历经五个月终于接收了,很开心,就是分低了点。希望AJP能再现辉煌。

    2

    展开2条回复
共56条页码: 1/6页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分